LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for high unmet medical needs, specifically treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company's pipeline includes lasofoxifene, a selective estrogen receptor modulator (SERM) in a Phase 3 trial for ESR1-mutated metastatic breast cancer, and ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system in Phase 2 planning for ALS. LeonaBio also explores early-stage compounds like ATH-1020 for neurological diseases. The company in-licensed global rights to lasofoxifene, excluding Asia and certain Middle Eastern countries, from Sermonix Pharmaceuticals, which had previously acquired rights from Ligand Pharmaceuticals and Pfizer. The lead candidate lasofoxifene was originally discovered through a collaboration between Pfizer and Ligand Pharmaceuticals and was previously approved in Europe for osteoporosis under the brand name Fablyn. LeonaBio targets patients with limited treatment options in oncology and neuroscience, aiming to advance these assets toward regulatory approval in the United States and Europe.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage investors.leonabio.com
Sector Healthcare IR page investors.leonabio.com
Tags
oncology, neurology, breast cancer, amyotrophic lateral sclerosis, selective estrogen receptor modulators, small molecule therapies, clinical-stage, drug development, lasofoxifene, ATH-1105, ATH-1020, Fablyn, ELAINE-1, ELAINE-2, ELAINE-3, Sermonix Pharmaceuticals, Ligand Pharmaceuticals, Pfizer
Press page —

Metrics

Valuation  
Market cap $ 35.439M
Market cap (USD) $ 35.439M
P/E -0.16
PEG —
P/BV 2.21
P/S —
P/OCF -0.47
P/FCF -0.36
Dividend yield —
Turnover / mcap —
Returns  
ROE -290.8%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 92.151M 58.779M 160.245M 258.153M 332.008M 279.563M 2.189M
Net profit -105.609M -96.94M -117.672M -95.639M -54.853M -19.955M -5.161M
Free cash flow — -97.203M -101.057M -73.61M -44.671M -26.433M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 7.57 — — — — — —
P/OCF -1.55 — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 1M 1.92M 1.91M 1.59M 1.22M 803,000
Cash and deposits (USD) 2.06M 60.6M 111M 96M 90.6M 48.4M 69.3M
Right-of-use assets (USD) — 936,000 1.46M 1.26M 1.05M 808,000 535,000
Cash flow detail
Operating cash flow (USD) -3.71M -24.1M -43.1M -72.5M -101M -97.2M -45.7M
Purchases of property, plant and equipment (USD) — -2.32M -1.57M -1.14M -304,000 -33,000 —
Change in payables (cash effect) (USD) 701,000 2.6M 5.15M 2.1M 7.37M -5.75M -21.3M
Share-based compensation (USD) 253,000 633,000 4.62M 10.6M 10.6M 11M 6.1M
Free cash flow (OCF - PPE - intangibles) (USD) — -26.4M -44.7M -73.6M -101M -97.2M —
Income detail
Research and development expense (USD) 3.79M 13.3M 42.8M 61.5M 93.8M 70.7M 17.5M
↳ 5y CAGR +79.5% +5.7%
Total comprehensive income (USD) -5.16M -19.9M -55.3M -97.2M -116M -96.6M -106M
Comprehensive income to owners (USD) -5.16M -19.9M -55.3M -97.2M -116M -96.6M -106M
Reported Mar 25, 2021 Mar 25, 2021 Mar 28, 2022 Mar 23, 2023 Feb 22, 2024 Feb 27, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

BOTHELL, Wash., November 16, 2026 – LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates.

“We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene.

LeonaBio, Inc. — Other Events Bull 0 Bear 0 Routine

In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.35 per share.

On September 18, 2026, the Series A Common Warrants became exercisable and will remain exercisable until October 19, 2026, in accordance with the terms and conditions of the Series A Common Warrants. If exercised in full for cash, the Series A Common Warrants would provide the Company with approximately $146.2 million of additional capital. Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including statements regarding the amount of proceeds, if any, the Company may receive upon exercise of the Series A Common Warrants.

September 3, 2026 at 7:00 AM EDT

PDF Version

BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY. Details are as follows:

Cantor Global Healthcare Conference 2026 Format: Fireside Chat Date and Time: Friday, September 11, 2026, from 9:45 am – 10:15 am EDT Location: New York, NY

A live webcast of the fireside chat can be accessed from the Investors section of the LeonaBio website at https://investors.leonabio.com/news-and-events/events-and-presentations-investor. An archived replay will be available for at least 30 days following the event.

About LeonaBio LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

Prompts

LeonaBio, Inc. (ticker LONA), listed in United States.

Company History

Date Change Detail
Jan 9, 2026 Renamed ATHIRA PHARMA, INC. → LEONABIO, INC.
Sep 19, 2019 Renamed M3 Biotechnology, Inc. → ATHIRA PHARMA, INC.
— Former tickers ATHA

ETFs Holding LeonaBio, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.40% 98,606 $ 272.153K Nov 17, 2026
DFSU 0.00% 330 $ 1,230.90 Nov 12, 2026
DCOR 0.00% 3,635 $ 13.559K Nov 12, 2026